Gynecologic Cancers

Pae was found to promote TRIM26 expression, which in turn enhanced TRIM26-mediated ubiquitination and degradation of LDHA, thereby contributing to glycolysis inhibition and suppression of EC progression. These results suggested that Pae might exert its effects by modulating the TRIM26/LDHA axis and supported its potential therapeutic value in EC.

Serum SCC-Ag showed superior prognostic performance compared with individual IHC markers, and may be useful for postoperative risk stratification in VSCC. Combined biomarker panels, including p53, PD-L1, EGFR and p16, yielded promising sensitivity, supporting future strategies.

ADARB1 exerts its anti-tumor effects primarily through the HMGB1/PFKFB3 pathway. Collectively, these findings identify ADARB1 as a novel tumor suppressor in cervical cancer and a promising therapeutic target for clinical intervention.

Notably, gene signatures from the two dominant Cyto_CD8+ subsets exhibited opposing prognostic roles when validated against human OC datasets (GSE18520, GSE26712, GSE49997). This study confirms the laying hen as a valuable OC model by demonstrating cross-species conservation in cellular heterogeneity and oncogenic pathways, advancing it from a pathologically analogous system to a molecularly traceable tool.

P=N/A, N=46, Recruiting, Baskent University

P2, N=244, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P2, N=25, Recruiting, Ohio State University Comprehensive Cancer Center

Ceralasertib monotherapy demonstrated promising anti-tumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATR inhibitors in this patient population.

The patient was started on prednisolone and azathioprine, which significantly improved her DM symptoms...Postpartum-onset DM presenting with malignant pleural effusion is rare and may signal an occult malignancy. This case highlights the importance of early cancer screening in similar presentations, as well as the need for a coordinated, multidisciplinary approach to optimize patient management and outcomes.

Despite major advances in molecular diagnostics, hereditary endometrial cancer remains frequently underdiagnosed, leading to missed opportunities for cancer prevention among affected individuals and their families. This comprehensive review summarises current evidence on hereditary predispositions to endometrial cancer, with a particular emphasis on Lynch syndrome, and discusses underlying genetic mechanisms, inheritance patterns, diagnostic strategies, and clinical implications for screening, genetic counselling, and treatment optimisation.

Multivariate Cox regression showed that a model of downregulated miR-16-5p and upregulated miR-451a was significantly associated with poorer survival (p = 0.023). This study indicates the future potential of exomiRs as diagnostic and prognostic liquid biopsy markers for vulvar cancer.

This classification (refined in ProMisE and TransPORTEC) enables precise treatment: immunotherapy (pembrolizumab, dostarlimab) works excellently in dMMR/MSI-H tumors, PI3K/AKT/mTOR inhibitors and trastuzumab deruxtecan in selected molecular subtypes, and hormone therapy in ER-positive tumors. Integrating the molecular profile with FIGO allows for truly personalized treatment, although MMRp/MSS tumors remain a challenge. The future lies in multi-omics, new biomarkers, and combination therapies.